Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Media ▼Online-CME News ▼Meeting Reports Slides ▼About

ACC 2020 ▼AHA 2020 ▼Covid-19 ▼Diabetes & CVD ▼ESC 2020 ▼HF Practical Tutorials ▼Kidney disease & CVD ▼

CVMC

Slides (curriculum) - May 9, 2013

Share this page with your colleagues and friends:

Continue reading:

4 Things a cardiologist should know about triglycerides

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

5 Things a cardiologist needs to know about GLP-1RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Similar risk of NACE when comparing two P2Y12 inhibitors in patients with ACS after PCI

Literature - Dec. 15, 2020 - You SC, et al. - JAMA. 2020

Comparison of two P2Y12 inhibitors in ACS patients with diabetes

Literature - Nov. 9, 2020 - Ndrepepa G, et al. - JACC Cardiovasc Interv 2020

Total CV events lowered by PCSK9i-induced Lp(a) reduction in ACS patients

Literature - Nov. 6, 2020 - Szarek M, et al. - Eur Heart J. 2020

Atherosclerosis

Silent CAD present in 4 out of 10 Swedish individuals

News - Nov. 14, 2020

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Elevated Lp(a) and family history of CHD have independent and additive joint associations with CV events

Literature - Sep. 7, 2020 - Mehta A et al., - J Am Coll Cardiol. 2020.

Atrial fibrillation

An overview of the global burden of CVD and risk factors from 1990 to 2019

Literature - Jan. 14, 2021 - Roth GA, et al. - J Am Coll Cardiol. 2020

NOAC non-inferior to warfarin in AF patients with bioprosthetic mitral valve

News - Nov. 15, 2020

Omega-3 fatty acids and/or vitamin D3 supplementation do not reduce incident AF

News - Nov. 14, 2020

BET Inhibition

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Primary endpoint not met for BET inhibitor in phase 3 trial

News - Sep. 30, 2019

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

Covid-19

Increased in-hospital mortality in COVID-19 patients with myocardial injury and echocardiographic abnormalities

Literature - Dec. 1, 2020 - Giustino G, et al. - J Am Coll Cardiol. 2020

Update on COVID-19 at AHA Scientific Sessions

10' education - Nov. 24, 2020 - Anthony Fauci, MD

COVID-19 and risk of HFpEF

News - Nov. 3, 2020

Covid-19, ACE2, RAASi

COVID-19, ACE2 and RAAS inhibition

Online-CME - This course consists of 3 parts.

COVID-19, ACE2 and RAAS inhibition

Lecture - Apr. 29, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD

CV Inflammation

COVID-19 and risk of HFpEF

News - Nov. 3, 2020

Total burden of serious CV events reduced by IL-1β inhibition

Literature - Oct. 26, 2020 - Everett BM et al. - J Am Coll Cardiol 2020

Strong evidence for colchicine in patients with chronic coronary disease

5' education - Oct. 7, 2020 - Aernoud Fiolet, MD and prof. Jan Hein Cornel, MD, PhD

CVRM

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

Persons with NAFLD are not automatically at high risk of acute MI or stroke

Literature - Nov. 4, 2019 - Alexander M et al, - BMJ 2019

Diabetes

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD

E-learning Reducing CV risk in diabetes

Online-CME - This course consists of 3 parts.

E-learning The evolving role of triglyceride-rich lipoproteins

Online-CME - This course consists of 3 parts.

Diabetes & CVD

E-learning 5 Things a cardiologist needs to know about GLP-1 RA

Online-CME - This course consists of 5 lectures.

SGLT2 inhibitor reduces total burden of CVD in patients with T2DM and ASCVD

Literature - Jan. 7, 2021 - McGuire DK, et al. - Lancet Diabetes Endocrinol 202

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD

Epigenetics in CVD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

BET inhibitor therapy did not meet primary endpoint of reducing MACE in post-ACS patients with T2DM

News - Nov. 17, 2019

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

ESC Diabetes guidelines 2019

Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale

Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

New ESC/EASD Guidelines on diabetes no longer regard metformin as first-line therapy

News - Sep. 3, 2019

ESC/EAS Guidelines dyslipidaemias 2019

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Slides: LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

Slides (presentation) - Sep. 9, 2019 - ESC Paris, France - Prof. Brian A. Ference, M.D, University of Cambridge, United Kingdom - CME symposium held during ESC 2019

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

Familial Hypercholesterolemia

PCSK9i siRNA therapy for lowering LDL-c levels approved by EC

News - Dec. 14, 2020

PCSK9 siRNA recommended by CHMP for EU approval

News - Oct. 28, 2020

ANGPTL3 inhibition reduces LDL-c in HoFH patients with limited to no LDL receptor activity

News - Oct. 6, 2020

German videos

Möglichkeiten in der Lipidtherapie die unabhängig vom LDL-c das residuale Risiko reduzieren

Residuales Risiko: Die Rolle der Hypertriglyceridämie

GLP-1 RA & CVD

E-learning 5 Things a cardiologist needs to know about GLP-1 RA

Online-CME - This course consists of 5 lectures.

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD

How do GLP-1RAs work?

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD

Heart Failure

Lower risk of HF hospitalizations with ferric carboxymaltose in patients with iron deficiency, stabilized after acute HF

Literature - Jan. 14, 2021 - Ponikowski P, et al. - Lancet 2020

Recommendation from FDA Advisory Committee for use of ARNI in HFpEF

News - Dec. 17, 2020

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD

HFpEF: The essentials to know

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

Hypertension

An overview of the global burden of CVD and risk factors from 1990 to 2019

Literature - Jan. 14, 2021 - Roth GA, et al. - J Am Coll Cardiol. 2020

Causal mechanism of age-related hypertension endotype identified

Literature - Dec. 8, 2020 - Elbatreek MH, et al. - PLoS Biol 2020

Moderate and heavy alcohol consumption associated with hypertension

Literature - Sep. 28, 2020 - Mayl JJ et al. - J Am Heart Assoc. 2020

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Kidney disease & CVD

Nonsteroidal MRA reduces kidney and CV risks in patients with CKD and T2DM with or without CVD

News - Nov. 24, 2020

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

Dual SGLT1 and SGLT2 inhibitor reduces CV outcomes in diabetes patients in two settings

News - Nov. 19, 2020

LDL-c Key Lessons

Key lessons on LDL-c and CV risk

LDL-c Key lessons

Screening for familial hypercholesterolemia after ACS pays off

LDL-c Key Lessons

LDL-c lowering treatment impacts disease progression before clinical manifestation

LDL-c Key Lessons

Lipids

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

E-learning The evolving role of triglyceride-rich lipoproteins

Online-CME - This course consists of 3 parts.

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD

Lp(a)

E-learning Lp(a), a new lipid frontier in CV risk management

Online-CME - This course consists of 3 parts.

Total CV events lowered by PCSK9i-induced Lp(a) reduction in ACS patients

Literature - Nov. 6, 2020 - Szarek M, et al. - Eur Heart J. 2020

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD

PCSK9

E-learning PCSK9i & LDL-c: Guidelines, Practice and Innovation

Online-CME - This course consists of 3 parts.

E-learning Lp(a), a new lipid frontier in CV risk management

Online-CME - This course consists of 3 parts.

PCSK9i reduces complex coronary disease that requires revascularization

News - Nov. 24, 2020

Pulmonary Arterial Hypertension

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Low-risk profile in pulmonary arterial hypertension patients predicts better survival

Literature - June 6, 2017 - Kylhammar D, et al. - Eur Heart J 2017

siRNA therapy and LDL-C

PCSK9i siRNA therapy for lowering LDL-c levels approved by EC

News - Dec. 14, 2020

PCSK9 siRNA recommended by CHMP for EU approval

News - Oct. 28, 2020

In high-risk primary prevention individuals, RNAi against PCKS9 reduces LDL-c

News - Oct. 6, 2020

Stroke

An overview of the global burden of CVD and risk factors from 1990 to 2019

Literature - Jan. 14, 2021 - Roth GA, et al. - J Am Coll Cardiol. 2020

P2Y12i combined with aspirin superior to aspirin in patients with ipsilateral atherosclerotic stenosis

News - Nov. 24, 2020

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

© 2006 - 2021 pace-cme.org - About